No Prescription |
 |
 | ||
|
GEMEZ Factive |
|
| ||
No Prescription » Prescription Drugs 8 » GEMEZ Factive Gemifloxacin is used to treat a variety of bacterial infections. This medication belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections. It will not work for virus infections (e.g. common cold flu). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.How to use Gemifloxacin OralRead the Patient Information Leaflet available from your pharmacist. If you have any questions consult your doctor or pharmacist.Take this medication by mouth with or without food usually once daily or as directed by your doctor. The dosage and length of treatment is based on your medical condition and response to treatment. Drink plenty of fluids while taking this drug unless your doctor tells you otherwise.Take this medication at least 2 hours before or 3 hours after taking any drugs that contain magnesium or aluminum. Some examples include quinapril certain forms of didanosine (chewable/dispersible buffered tablets or pediatric oral solution) vitamins/minerals and antacids. Follow the same instructions if you take bismuth subsalicylate iron and zinc. Gemifloxacin should be taken at least 2 hours before sucralfate. These medications bind with gemifloxacin and prevent its full absorption.Antibiotics work best when the amount of medicine in your body is kept at a constant level. It is important not to miss a dose. To help you remember take this medication at the same time every day.Continue to take this medication until the full prescribed amount is finished even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow which may result in a return of the infection.Tell your doctor if your condition persists or worsens.Gemifloxacin Oral is used to treat the following:Pneumonia caused by Pneumococcus Bacteria Bacterial Pneumoniae caused by Klebsiella Pneumoniae Bacterial Pneumonia caused by Haemophilus Influenzae Pneumonia caused by the Bacteria Moraxella Catarrhalis Pneumonia caused by Bacteria Pneumonia caused by Mycoplasma Pneumoniae Pneumonia caused by the Bacteria Chlamydia Bacterial Infection with Chronic Bronchitis Severe Episode of Chronic Bronchitis due to H. Flu Severe Episode of Chronic Bronchitis by M. Catarrhalis Severe Episode of Chronic Bronchitis due to Streptococcus Pneumoniae Buy GEMEZ Factive and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About GEMEZ Factive: Product Type: Prescription Drugs 8 GEMEZ ( Factive Generic Gemifloxacin ) GEMEZ (Factive Generic Gemifloxacin) Factive Generic Gemifloxacin 320mg 2 x 50 Tablets 50 Tablets 4 x 50 Tablets Factive Generic Gemifloxacin GEMEZ
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
